All the contents of this article are from official and reliable sources, and the specific information is detailed at the end of the article."
Preface
He was originally a small technician, but he became the director of a pharmaceutical factory in the gears of fate.
Take on the responsibility of saving a pharmaceutical company on the verge of bankruptcy, and bring the company back to life with an innovative drug.
Later, it made a fortune by relying on generic drugs, and developed a variety of innovative drugs, completely gaining a firm foothold in the pharmaceutical industry and becoming the "Moutai of the pharmaceutical industry".
But just when he retired and was ready to enjoy the leisurely retirement of retirement, the company became stormy, and its market value shrank by more than 400 billion yuan.
As a last resort, a year after his retirement, he could only return to the battlefield and lead the company back to the top again.
He is Sun Piaoyang.
A person who seems to have a very random name, but is very serious in life.
Medicine grass
Jiangsu Hengrui Pharmaceutical Co., Ltd., formerly known as Lianyungang Pharmaceutical Factory, is a large-scale listed pharmaceutical enterprise integrating scientific research, production and sales.
At present, Hengrui has 11 innovative drugs, covering VEGF, PD-1, PARP and other targets, involving tumors, hematology, analgesia, anesthesia and hypoglycemic therapeutic fields.
By the end of 2022, Hengrui pharmaceutical products have entered more than 40 countries and have broad prospects in the pharmaceutical market.
And Hengrui Pharmaceutical can have such achievements in the pharmaceutical industry, and there is one person who has contributed a lot.
He is Sun Piaoyang.
Many people don't have any impression of this person, and they will feel that the name is somewhat similar to a certain shampoo, but his achievements are unparalleled.
He is on the rich list all year round, but he is still low-key and unknown.
If it weren't for Hengrui Pharmaceutical's rapid growth in market value from 50 billion to 400 billion in just five years, everyone would not know that there is such a number one person in the pharmaceutical market.
2014 was a year of great significance for Sun Piaoyang.
This year, Hengrui's innovative drug apatinib, which brought hope to patients with advanced gastric cancer, was successfully launched.
Later, Hengrui Pharmaceutical successively launched innovative drugs such as cyclophosphamide and oxaliplatin, which were also listed in Europe and the United States.
With these drugs, from 2014 to 2019, Hengrui's market value soared.
But in fact, Hengrui's innovative drugs only drove Hengrui's own valuation, but the company's main income still relies on generic drugs.
In fact, China's pharmaceutical market has always been dominated by generic drugs, which do not require too much R&D effort and financial resources, and can have a larger market than innovative drugs.
Just like what was said in the movie "I Am Not the God of Medicine", a bottle of innovative medicine costs 37,000.
Generic drugs with similar functional utility only cost a few thousand yuan, and the huge price difference between the two is the reason why most people accept generic drugs.
And Sun Piaoyang's generic drugs may be cheaper than those in the movie, so there will be a broad market space and profit margins.
But Sun Piaoyang is not like a pharmaceutical company that is obsessed with corporate interests, only looking at the immediate profits, but he takes out all 10% of the profits and invests them in innovative drugs.
In 2016, Hengrui Pharmaceutical and Sun Piaoyang's alma mater, China Pharmaceutical University, established the joint laboratory of "Hengrui Pharmaceutical China Pharmaceutical University".
In 2018, Sun Piaoyang invested 2.67 billion yuan in R&D, and R&D accounted for 15.33% of revenue.
In 2019, Hengrui's R&D expenses doubled again to 3.896 billion yuan, and R&D investment accounted for 16.73% of revenue.
It is precisely because of Sun Piaoyang's major research and development that Hengrui has so many innovative drugs, and the market value is constantly being valued higher, and Sun Piaoyang has also ascended to the position of the richest man, and is known as "R&D first brother" and "God of Medicine".
But in the pharmaceutical industry, not everyone dares to invest so much in research and development like Sun Piaoyang, because the risks to be borne are very large, and once it fails, it is not something that an enterprise can afford.
However, Sun Piaoyang firmly believes that innovative drugs are the core of the pharmaceutical industry, and only with excellent technology can they not be choked by others.
A patent saves a business
People who are engaged in technology don't seem to be good at words, but professionally they definitely croak.
The so-called people don't talk much, probably like Sun Piaoyang.
After graduating from China Pharmaceutical University, he was admitted to the Department of Chemistry of Nanjing University as a graduate student majoring in organic chemistry out of his love for the pharmaceutical industry.
After several years of accumulation of academic career, he graduated and directly entered Lianyungang Pharmaceutical Factory as a technician.
The pharmaceutical factory itself is a good enterprise, but after the market economy was liberalized at that time, the Lianyungang pharmaceutical factory was already going downhill.
In addition, the production equipment of pharmaceutical factories is backward, and the products are even more single and have no technical content, so they produce some disinfectant water and purple water, and there is no room for survival at all.
Such a working environment makes Sun Piaoyang very helpless, because his identity as a newcomer is not taken seriously, and he has no right to take care of some things.
But he still seeks his own politics in his position and focuses on doing his job well.
It was his conscientious and responsible attitude that soon a highly educated talent like him was transferred to a pharmaceutical industry company as the deputy chief of the scientific research department.
Here, Sun Piaoyang met his Bole Xu Weiyu.
Xu Weiyu thinks that Sun Piaoyang is a very capable person and hopes that he can enliven the pharmaceutical factory.
Soon after, Sun Piaoyang was transferred back to Lianyungang Pharmaceutical Factory again, but this time he came back as the deputy director.
Although he is no longer an inconspicuous technician, the position of deputy factory director is still very awkward, and he cannot make decisions on everything.
Later, Xu Weiyu stared at the pressure, Sun Piaoyang was promoted to factory director, and Sun Piaoyang could let go of his hands and feet to do what he wanted to do.
After taking office, Sun Piaoyang decided to transform the factory and make innovative drugs.
As soon as this decision came out, it was opposed by everyone.
At that time, the pharmaceutical factory only had a profit of 80,000 yuan on its books, and there were more than 300 employees in the factory waiting to support their families.
In the eyes of the public, this is undoubtedly an unknown adventure for the technological innovation of the factory on the verge of closure.
Everyone doesn't want to risk their lives, not to mention that the pharmaceutical factory itself is mainly based on OEM processing, and if you really want to research new drugs, you don't know what the future will be.
But Sun Piaoyang did not give up, he called everyone to do the work one by one, and finally used a sentence: "You have no technology, fate is in the hands of others, we have to grasp fate in our own hands." ”
The crowd woke up.
After that, Sun Piaoyang took the new technology as a breakthrough and began to carry out technical information in the pharmaceutical factory.
In his second year in office, Sun Piaoyang found that there was a drug for cancer chemotherapy that was very hot in the market.
But the one is in the form of a needle, and it's expensive.
He was going to get into the drug, but he couldn't technically reach it.
In the end, Sun Piaoyang thought of a way to make the injection into a capsule, which solved many technical problems.
As soon as the drug was listed, it became popular, and with this cancer chemotherapy drug, the pharmaceutical company suddenly earned 1.2 million, and the whole factory was overjoyed, as if they saw new hope.
Just when everyone was immersed in joy, Sun Piaoyang's decision once again poured cold water on everyone.
Sun Piaoyang decided to take 1.2 million to buy a patent called cyclophosphoramide, which once again aroused opposition from the public.
But this time Sun Piaoyang has a tough attitude, he knows that if the pharmaceutical company wants to go on, only by constantly emerging innovative drugs can it be defeated.
This time, Sun Piaoyang made the right bet again.
With the launch of this drug, the valuation of the pharmaceutical company has continued to increase, and it has become a leader in the industry.
Up and down the audience, no one objected to Sun Piaoyang's decision, and as long as it was Sun Piaoyang's decision in the future, no one dared to oppose it.
Innovative drugs not only convinced the whole factory, but even Sun Piaoyang strengthened his determination to make innovative drugs, which is also the cornerstone of Hengrui becoming a leader in the pharmaceutical industry in the future.
But Sun Piaoyang is not so lucky every time, especially in the market economy, Hengrui has also been stormy.
A storm is coming
In 2021, with the country's anti-corruption work in the medical industry, Hengrui, as a pharmaceutical giant, was also involved, and various media in the society broke out: Hengrui's leaders were arrested, the company was investigated and other negative news that was unfavorable to the company.
And Hengrui also clarified to the outside world at the first time, but it inevitably became the center of the storm, so that Hengrui's stock price instantly evaporated 400 billion.
Moreover, during that time, Hengrui's shareholders and senior management resigned one after another, which also caused a lot of impact on the outside world, so that the stock price was unstable.
At this time, Sun Piaoyang had retired and stayed at home for a year.
But the stormy Hengrui still made him dare not retire, so he was pushed to the position of chairman again.
In desperation, Sun Piaoyang could only put himself into work again.
The outside world is also very optimistic about Sun Piaoyang's return, after all, Sun Piaoyang's achievements in the pharmaceutical industry are obvious to all.
Sun Piaoyang also used his strength to impress the outside world again.
In just three years, Hengrun has gone from not being optimistic to the stock price rebounding, and the results have once again amazed everyone.
As of December 31, 2023, Hengrui Pharmaceutical's revenue in 2023 was 22.82 billion yuan, an increase of 7.26% from 21.275 billion yuan in the same period last year.
epilogue
After experiencing a downturn, Hengrui is now returning to the normal track again under the leadership of Sun Piaoyang, although the overall growth is relatively slow, but under the influence of many unfavorable factors such as repeated medicine and medical insurance with volume purchasing, it is rare to maintain this growth rate.
But the pharmaceutical industry is still very volatile, and Sun Piaoyang wants to lead Hengrui to go through the road of nationalization, which is also a big challenge at present.
For Hengrui Pharmaceutical, are you optimistic about its development?
Resources: